Syed Khizer Hasan

List of Publications by Citations

43 papers	560 citations	13 h-index	22 g-index
47 ext. papers	657 ext. citations	4.3 avg, IF	3.18 L-index

#	Paper	IF	Citations
43	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. *Blood*, **2008**, 112, 3383-90	2.2	68
42	Understanding the molecular pathogenesis of acute promyelocytic leukemia. *Best Practice and Research in Clinical Haematology*, **2014**, 27, 3-9	4.2	55
41	Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. *Blood*, **2010**, 115, 326-30	2.2	55
40	Acute myeloid leukemia developing in patients with autoimmune diseases. *Haematologica*, **2012**, 97, 805-17	6.6	50
39	Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. *Neurology*, **2011**, 76, 1059-65	6.5	32
38	Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. *British Journal of Haematology*, **2013**, 161, 533-40	4.5	30
37	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. *Genes Chromosomes and Cancer*, **2010**, 49, 726-32	5	29
36	Molecular pathogenesis of secondary acute promyelocytic leukemia. *Mediterranean Journal of Hematology and Infectious Diseases*, **2011**, 3, e2011045	3.2	23
35	Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. *Haematologica*, **2011**, 96, 621-5	6.6	21
34	Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. *Genes Chromosomes and Cancer*, **2009**, 48, 213-21	5	20
33	Childhood CML in India: b2a2 transcript is more common than b3a2. *Cancer Genetics and Cytogenetics*, **2006**, 169, 76-7		19
32	The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. *Blood*, **2015**, 125, 600-5	2.2	14
31	Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia. *International Journal of Cancer*, **2018**, 142, 2175-2185	7.5	13
30	Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. *Leukemia Research*, **2012**, 36, 474-8	2.7	12
29	Biology and management of therapy-related acute promyelocytic leukemia. *Current Opinion in Oncology*, **2013**, 25, 695-700	4.2	12
28	A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1. *Blood Cancer Journal*, **2019**, 9, 79	7	11
27	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. *Leukemia*, **2019**, 33, 1527-1530	10.7	10

26	Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML). *Leukemia*, **2021**, 35, 1392-1404	10.7	10
25	Impact of FLT3 internal tandem duplications on Indian acute promyelocytic leukemia patients: prognostic implications. *Hematology*, **2007**, 12, 99-101	2.2	9
24	Two novel methods for rapid detection and quantification of DNMT3A R882 mutations in acute myeloid leukemia. *Journal of Molecular Diagnostics*, **2015**, 17, 179-84	5.1	7
23	Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. *Annals of Hematology*, **2013**, 92, 1319-23	3	7
22	Acute promyelocytic leukemia with secondary myelofibrosis -- case report and review of the literature. *American Journal of Hematology*, **2006**, 81, 476-7	7.1	7
21	Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context. *Frontiers in Oncology*, **2019**, 9, 450	5.3	6
20	Longitudinal detection of DNMT3A transcripts in patients with acute myeloid leukemia. *American Journal of Hematology*, **2018**, 93, E120-E123	7.1	6
19	Molecular Heterogeneity in Acute Promyelocytic Leukemia - a Single Center Experience from India. *Mediterranean Journal of Hematology and Infectious Diseases*, **2018**, 10, e2018002	3.2	5
18	Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23). *Genes Chromosomes and Cancer*, **2014**, 53, 248-54	5	5
17	Long term clinical outcomes of adult hematolymphoid malignancies treated at Tata Memorial Hospital: An institutional audit. *Indian Journal of Cancer*, **2018**, 55, 9-15	0.9	5
16	Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39. *Breast Cancer Research and Treatment*, **2020**, 179, 731-742	4.4	5
15	miRNA-mRNA Profiling Reveals Prognostic Impact of Expression in Acute Myeloid Leukemia. *Oncology Research*, **2020**, 28, 321-330	4.8	3
14	Studies of protein-protein interactions in Fanconi anemia pathway to unravel the DNA interstrand crosslink repair mechanism. *International Journal of Biological Macromolecules*, **2017**, 104, 1338-1344	7.9	3
13	Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders. *American Journal of Hematology*, **2014**, 89, 346-7	7.1	2
12	Over-representation of bcr3 subtype of PML/RARalpha fusion gene in APL in Indian patients. *Annals of Hematology*, **2005**, 84, 781-4	3	2
11	Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. *Leukemia and Lymphoma*, **2018**, 59, 1268-1270	1.9	1
10	Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia. *Hematological Oncology*, **2020**, 38, 808-816	1.3	1
9	Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-β/SMAD signaling. *Breast Cancer Research and Treatment*, **2021**, 185, 317-330	4.4	1

8	Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy. *Medical Oncology*, **2020**, 37, 48	3.7	0
7	Structural and biophysical properties of h-FANCI ARM repeat protein. *Journal of Biomolecular Structure and Dynamics*, **2017**, 35, 3032-3042	3.6	0
6	Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10 Suppl 3, S139-43	2	
5	Timing of allogeneic BMT for CML patients in India: does it affect response?. *American Journal of Hematology*, **2007**, 82, 329	7.1	
4	Minimal Residual Disease by Multiparametric Flow Cytometry Predicts Relapse Free Survival better than Over-Expression of WT1 and BAALC in Acute Myeloid Leukemia. *Blood*, **2014**, 124, 1064-1064	2.2	
3	Molecular Characterization of the t(15;17)(q22;21) in Epirubicin-Related Acute Promyelocytic Leukaemia. *Blood*, **2008**, 112, 791-791	2.2	
2	The Pathophysiology of Acute Promyelocytic Leukemia161-168		
1	Acute promyelocytic leukemia: pathophysiology and clinical results update131-140		